Plus Therapeutics (PSTV – Research Report) received a Buy rating and a $6.00 price target from Maxim Group analyst Jason
Tag: Jason McCarthy
Analysts’ Top Healthcare Picks: Brainstorm Cell Therapeutics (BCLI), SLANG Worldwide (SLGWF)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Brainstorm Cell
OncoSec Medical (ONCS) Gets a Buy Rating from Maxim Group
In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to OncoSec Medical (ONCS – Research
Lineage Cell Therapeutics (LCTX) Gets a Buy Rating from Maxim Group
Maxim Group analyst Jason McCarthy reiterated a Buy rating on Lineage Cell Therapeutics (LCTX – Research Report) yesterday and set
Maxim Group Gives a Buy Rating to Inmune Bio (INMB)
In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to Inmune Bio (INMB – Research
Analysts’ Opinions Are Mixed on These Healthcare Stocks: VistaGen Therapeutics (NASDAQ: VTGN), Amneal Pharmaceuticals (NYSE: AMRX) and Sarepta Therapeutics (NASDAQ: SRPT)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on VistaGen Therapeutics (VTGN – Research
Co-Diagnostics (CODX) Gets a Buy Rating from Maxim Group
In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to Co-Diagnostics (CODX – Research Report),